IL2 and cancer: To determine if the observed effects of HD IL-2 on glucocorticoid-mediated mouse thymic output and naïve T cells also occurred clinically, PBMCs were obtained from consenting cancer patients undergoing HD IL-2 therapy both before treatment and throughout the course of 1-4 weeks after, which were used to perform T-cell phenotyping (Figure 3A).